HomeCompareBMY vs TGS

BMY vs TGS: Dividend Comparison 2026

BMY yields 4.17% · TGS yields 2.74%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGS wins by $267.38M in total portfolio value· pulled ahead in Year 2
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
TGS
TGS
● Live price
2.74%
Share price
$34.68
Annual div
$0.95
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$267.50M
Annual income
$249,968,045.94
Full TGS calculator →

Portfolio growth — BMY vs TGS

📍 TGS pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYTGS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + TGS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
TGS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
TGS
Annual income on $10K today (after 15% tax)
$232.84/yr
After 10yr DRIP, annual income (after tax)
$212,472,839.05/yr
At 15% tax rate, TGS beats the other by $212,438,988.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + TGS for your $10,000?

BMY: 50%TGS: 50%
100% TGS50/50100% BMY
Portfolio after 10yr
$133.81M
Annual income
$125,003,934.80/yr
Blended yield
93.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
TGS
Analyst Ratings
2
Buy
1
Sell
Consensus: Buy
Altman Z
3.1
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
TGS buys
0
No recent congressional trades found for BMY or TGS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYTGS
Forward yield4.17%2.74%
Annual dividend / share$2.49$0.95
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%100%
Portfolio after 10y$120.5K$267.50M
Annual income after 10y$39,823.66$249,968,045.94
Total dividends collected$91.0K$266.18M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy

Year-by-year: BMY vs TGS ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrTGS PortfolioTGS Income/yrGap
1$11,271$571.12$11,248$547.87+$23.00BMY
2← crossover$12,884$824.20$13,187$1,151.84$303.00TGS
3$14,993$1,206.32$16,634$2,524.15$1.6KTGS
4$17,839$1,797.27$23,750$5,951.38$5.9KTGS
5$21,826$2,738.11$41,295$15,882.70$19.5KTGS
6$27,643$4,289.31$95,805$51,618.57$68.2KTGS
7$36,534$6,955.64$326,351$223,840.07$289.8KTGS
8$50,861$11,770.13$1,774,419$1,425,223.14$1.72MTGS
9$75,402$20,980.23$16,383,022$14,484,394.34$16.31MTGS
10$120,504$39,823.66$267,497,880$249,968,045.94$267.38MTGS

BMY vs TGS: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

TGSStock

Transportadora de Gas del Sur S.A. engages in transportation of natural gas, production, and commercialization of natural gas liquids in Argentina. The company operates through four segments: Natural Gas Transportation Services; Liquids Production and Commercialization; Other Services; and Telecommunications. The Natural Gas Transportation segment transports natural gas through 5,769 miles of pipeline system to distribution companies, power plants, and industrial customers. It also provides operation and maintenance services for the natural gas transportation facilities. The company's Liquids Production and Commercialization segment produces and commercializes natural gas liquids, such as ethane, liquid petroleum gas, natural gasoline, propane, and butane in Argentina and internationally. Its Other Services segment offers midstream services, including natural gas treatment, separation, and removal of impurities from the natural gas stream, as well as natural gas compression. It also provides services related to pipeline and compression plant construction, operation, and maintenance; and generates steam for electricity production. The Telecommunications segment provides telecommunication services with a network that includes a microwave digital network with synchronous digital hierarchy technology and a dark fiber optic network. As of December 31, 2021, it served 6.2 million residential, commercial, industrial, and electric power generation end users. The company was founded in 1992 and is headquartered in Buenos Aires, Argentina. Transportadora de Gas del Sur S.A. is a subsidiary of Compañía de Inversiones de Energía S.A.

Full TGS Calculator →
📬

Get this BMY vs TGS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.